Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04653246
Title Phase 2, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Jacob Laubach
Indications
Therapies
Age Groups: senior
Covered Countries USA

Facility Status City State Zip Country Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field